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Abstract
Pentraxin 3 (PTX3) is a soluble pattern recognition receptor that binds with high affinity and selectivity to
fibroblast growth factor-2 (FGF2), thus inhibiting its pro-angiogenic activity. Here we investigated the effects of
PTX3 on monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patient-
derived bone marrow (BM) plasma cells (PCs), endothelial cells (ECs), and fibroblasts (FBs), and assessed whether
PTX3 can modulate the cross-talk between PCs and those microenvironment cells. PTX3 and FGF2 expression was
evaluated by ELISA. Functional studies, including cell viability, wound healing, chemotaxis, and Matrigel
®
assays,
were performed on MGUS and MM ECs and FBs upon the PTX3 treatment. Through western blot PTX3-induced
modulation in FGF2/FGF receptor signalling pathways was evaluated in MGUS and MM ECs and FBs through
western blot. Co-cultures between MM ECs/FBs and human PC lines were used to evaluate possible PTX3 indirect
effects on MM PCs. Adhesion molecules were studied by flow cytometry. PTX3 provides a direct time- and
dose-dependent apoptotic effect on MM ECs and FBs, but not on either MM primary PCs or human PC lines.
PTX3 inhibits migration of MM ECs and FBs in a dose-dependent manner, and impacts in vitro and in vivo
FGF2-mediated MM angiogenesis. Co-cultures of PCs and ECs/FBs show that PTX3 treatment indirectly impairs
PC viability and adhesion. We conclude that PTX3 is an anti-angiogenic factor in MM and behaves as a cytotoxic
molecule on MM cells by inhibiting the cross-talk between PCs and ECs/FBs.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Multiple myeloma (MM) remains an incurable disease,
despite conventional and high-dose chemotherapies [1].
Molecules targeting not only plasma cells (PCs) but
also bone marrow (BM) stromal cells (BMSCs) such
as endothelial cells (ECs) and fibroblasts (FBs) are
needed to overcome drug resistance [2]. Angiogenesis
is a constant component of the MM microenvironment
[3]. It results from a prevalence of activatory over
inhibitory interactions between PCs and BMSCs, and
ultimately guides the survival and drug resistance of
PCs [4]. It takes place with the ‘angiogenic switch’
in step with transition from the avascular phase of
the monoclonal gammopathy of undetermined signif-
icance (MGUS) to the vascular phase of active MM
[3]. On the switch, pro-angiogenic factors overcome
the anti-angiogenic ones [5], and fibroblast growth
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factor-2 (FGF2), a heparin-binding protein, plays a
pivotal role among the former [6]. It acts as both an
autocrine and a paracrine factor on PCs, ECs, and FBs
[7], being a potent mitogen for these cells, and induc-
ing their migration and differentiation [7–9]. Pentraxin
3 (PTX3), a 41-kDa glycosylated protein assembled
in 10–20 mer multimers [10], is a prototypic mem-
ber of the long pentraxin subfamily [11], a soluble
pattern recognition receptor, and an anti-angiogenic
factor [12,13]. Its unique N-terminal domain contains
a (97–110) amino acid sequence that binds FGF2
with high affinity and selectivity [14,15]. This pre-
vents FGF2 binding to cognate receptors (FGFRs)
and heparan-sulphate proteoglycans, as demonstrated
in human and bovine normal ECs [8], thus halting
the FGF2 pro-angiogenic activity [8,16]. Accordingly,
PTX3 inhibits EC proliferation and migration, and
FGF2-dependent neovascularization in chick embryo
chorioallantoic membrane (CAM) [15]. PTX3 is pro-
duced in various physiopathological conditions by ECs
and FBs [17,18].
Here we wondered whether PTX3 plays a role in
the modulation of EC and FB activities that lead to
MM-associated angiogenesis and of PC viability and
adhesion to those stromal cells. By studying how PTX3
interferes with the cross-talk between the stromal cells
and PCs, we demonstrate that FGF2 is more expressed
than PTX3 in the BM microenvironment of MM versus
MGUS and control subjects, and that PTX3 inhibits EC
and FB activities and PC adhesion to these cells in MM
patients and behaves as an indirect cytotoxic molecule
on PCs. Our observations point to PTX3 as a potential
anti-angiogenic factor that could be employed to re-
establish a physiological FGF2/PTX3 ratio in the MM
microenvironment.
Materials and methods
Patients and controls
The BM aspirates from patients fulfilling the Interna-
tional Myeloma Working Group diagnostic criteria for
active MM (n = 35) and MGUS (n = 24) were stud-
ied. MM patients (20 males and 15 females) were aged
47–86 (median 63.5) years and D&S staged as IIA
(n = 8), IIB (n = 6), IIIA (n = 16), and IIIB (n = 5);
the M-component was IgG (n = 20), IgA (n = 9), and
κ or λ (n = 6). MGUS patients (14 males and 10
females) were aged 41–80 (median 61.5) years and
were IgG (n = 12), IgA (n = 8) or κ or λ (n = 4).
Normal (control) ECs and FBs were derived from 14
subjects with anaemia due to iron or vitamin B12 defi-
ciency (age range: 48–79 years; median: 62.8 years)
[19]. The study was approved by the Ethics Commit-
tee of the University of Bari Medical School and all
patients gave their informed consent in accordance with
the Declaration of Helsinki.
Cell cultures, plasma, and conditioned media
BM mononuclear cells were harvested from aspirates
by Ficoll gradient. ECs, FBs, and PCs were isolated
with specific magnetic microbeads as described previ-
ously [4]. Conditioned media (CM) were prepared as
described previously [20]. Plasma was separated from
BM aspirates. Methods are described in detail in the
Supplementary materials and methods.
Reagents
Recombinant human PTX3 (provided by Dr Bottazzi)
was dissolved in PBS, pH 7.0 and used at 33–198
nM in in vitro assays and at 0.11 and 0.22 nM in
the in vivo CAM assay as previously assessed [15].
Recombinant human FGF2 and VEGF (Peprotech,
London, UK) were dissolved at 0.1 M in 5 mM Tris,
pH 7.6 with 150 mM NaCl and used at 0.58 and 0.26
nM, respectively.
Functional studies
Viability, wound healing, chemotaxis, Matrigel® , chick
embryo chorioallantoic membrane (CAM), and adhe-
sion assays were performed as previously described
[21–24] and are described in detail in the Supplemen-
tary materials and methods.
Adhesion molecules analysis
Plasma cell lines RPMI8226 and U266 (both at 5 × 105
per dish) and MM ECs and FBs (both at 2.5 × 104
per dish) were seeded in 3.5 cm2 dishes with SFM
alone or supplemented with 0.58 nM FGF2 alone or
with 66 and 132 nM PTX3. After 24 h, cells were
analysed (CD11a, CD54, CD49d, CD49e, CD29) by
a FACSCanto II cytofluorimeter (BD Biosciences, San
Jose´, CA, USA) using the FlowJo software (Tree Star,
Ashland, OR, USA). Methods are described in detail
in the Supplementary materials and methods.
Western blotting and ELISA
Protein lysates (30 μg) from MM ECs and FBs, seeded
in SFM supplemented with 0.58 nM FGF2 and PTX3
(0, 66, and 132 nM) for 15 min, were separated on
4–12% NuPAGE Novex Bis-Tris gels (Invitrogen,
Carlsbad, CA, USA) [21]. Primary antibodies to Akt,
phospho(p)-Akt, Src, p-Src, Erk1/2, p-Erk1/2, NFκB,
p-NFκB (Cell Signaling Technology, Denvers, MA,
USA), and anti-tubulin antibody (as loading control;
Cell Signaling Technology) were used. NFκB and p-
NFκB were analysed in MM ECs and FBs seeded in
SFM supplemented with 0.58 nM FGF2 and PTX3 (0,
66, and 132 nM) for 25 min and then treated with
TNF-α (10 ng/ml) for 10 min, as previously described
[21]. The secreted PTX3 and FGF2 were quantified
in CM and BM plasma by an ELISA (R&D Systems,
Minneapolis, MN, USA).
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Co-cultures of MM ECs and FBs with PC lines
MM ECs and FBs (both at 2.5 × 104 per dish) from
five active MM patients were co-cultured in 24-well
plates with paired MM PCs or RPMI8226 or U266 cells
(5 × 104 per well), with or without transwell insert,
and treated with 66 and 132 nM PTX3. The PC lines
were previously marked with Carboxyfluorescein N-
succinimidyl ester (CFSE) to discriminate PCs from
the adherent ECs and FBs. Apoptosis of MM ECs,
FBs, and PCs was determined using PE Annexin V/7-
Amino-actinomycin D (7-AAD; BD Biosciences) and
the FACSCanto II cytofluorimeter.
Results
PTX3 and FGF2 expression in bone marrow PCs, ECs,
and FBs, and plasma of MM versus MGUS patients
and control subjects
First, we measured FGF2 and PTX3 levels in CM of
all cytotypes and found their significant increase in
ECs and FBs of MM versus MGUS patients and con-
trol subjects (Figures 1A and 1B). Since angiogenesis
results as a balance between pro- and anti-angiogenic
factors, data were analysed as FGF2/PTX3 ratio.
According to their pro-angiogenic state, MM patients
showed a ratio significantly higher than that of MGUS
patients (Figure 1C): indeed, it was increased in MM
PCs, ECs, and FBs compared with the MGUS counter-
parts. FGF2 and PTX3 levels were also assessed in BM
plasma. As shown in Figure 1D, the FGF2/PTX3 ratio
was higher in MM than in MGUS. Notably, control
subjects overlapped MGUS patients (Figure 1D).
PTX3 impacts FGF2-dependent activities of MM ECs
and FBs
Based on the above evidence, the effect of PTX3 on
FGF2-dependent EC (Figure 2A) and FB (Figure 2B)
functional activities was investigated next. ECs and
FBs from MM and MGUS patients and from con-
trol subjects were stimulated with 0.58 nM FGF2 and
treated with increasing doses of PTX3. The viabil-
ity of FGF2-exposed MM ECs and FBs was dose-
dependently affected by PTX3: at 24 h, 66 and 132
nM PTX3 reduced MM EC viability by 24% and
41%, respectively, and maximal inhibition (55%) was
obtained at 198 nM (Figure 2A). Similar effects were
observed on FB viability, with maximal inhibition
(41%) again at 198 nM (Figure 2B). These effects were
absent or marginal in MGUS ECs and FBs, as well
as in cells isolated from control subjects (Supplemen-
tary Figures 1 and 2). Of note, normal ECs (HUVECs)
and normal FBs (WI-38) overlapped controls (data not
shown). MM ECs and FBs treated with just PTX3 but
not FGF2 displayed only a marginal inhibitory effect
(−21% and −20% at 198 nM, respectively), due to the
seizure of only endogenous FGF2 (data not shown).
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Figure 1. FGF2 and PTX3 production in PC, EC, and FB conditioned media and in BM plasma. FGF2 (A) and PTX3 (B) levels in the conditioned
media of plasma cells (PCs), endothelial cells (ECs), and fibroblasts (FBs) as well as in BM plasma of 14 control subjects, 24 MGUS, and 35
active MM patients were examined by ELISA. Values are expressed as mean ± standard deviation. FGF2/PTX3 ratios were calculated in
conditioned medium (C) and BM plasma (D). ∗p < 0.03, ∗∗p < 0.01; Wilcoxon signed-rank test.
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Figure 2. PTX3 affects MM endothelial cell (EC) and fibroblast (FB) functional activities. Viability, chemotaxis, and wound healing assays
were performed on ECs (A) and FBs (B) isolated from the BM of 27 MM patients and cultured in triplicate in serum-free medium (SFM) and
SFM supplemented with FGF2 (0.58 nM) and PTX3 doses (0, 33, 66, 99, 132, and 198 nM). Wound healing assays from a representative
patient are shown. ∗p < 0.03, ∗∗p < 0.01; Wilcoxon signed-rank test.
PTX3 also inhibited EC and FB migration in a dose-
dependent manner in MM but not in MGUS patients,
as assessed by a chemotaxis (directional migration)
and a wound (random migration) assay. Chemotaxis of
MM ECs was inhibited by 50% and 72% (Figure 2A),
and that of FBs by 29% and 61% (Figure 2B), at 66
and 132 nM PTX3, respectively. In the corresponding
MGUS cells and in control subjects’ ECs and FBs,
the inhibitory effect was only marginal (Supplementary
Figures 1 and 2). Migration to heal the wound was
impacted in a dose-dependent fashion by PTX3 on
MM ECs (Figure 2A) and FBs (Figure 2B). These
effects were again marginal in MGUS ECs and FBs,
as well as in control subjects’ cells (Supplementary
Figures 1 and 2). HUVECs and WI-38 cells behaved
like the corresponding MGUS and control cells (data
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Figure 3. PTX3 does not affect VEGF-dependent functional activities of MM endothelial cells (ECs). Viability, chemotaxis, and wound
healing assays were performed on ECs isolated from the BM of 27 MM patients and cultured in triplicate in serum-free medium (SFM) and
SFM supplemented with VEGF (0.26 nM) and PTX3 doses (0, 33, 66, 99, 132, and 198 nM). Wound healing assays from a representative
patient are shown. ns = not significant; Wilcoxon signed-rank test.
not shown). When cells were exposed to VEGF instead
of FGF2, PTX3 was not able to antagonize viability
and migratory activity exerted by VEGF on MM ECs
(Figure 3), indicating that PTX3 specifically affects
FGF2-dependent cell functions.
PTX3 inhibits FGF2-dependent angiogenesis in MM
On the Matrigel® in vitro angiogenesis assay, PTX3
caused dose-dependent inhibition of vessel mesh areas,
length, and branching points on FGF2-stimulated MM
ECs (Figure 4A), but not in stimulated control subjects’
and MGUS ECs (Supplementary Figure 3). Further-
more, the inhibitory effect of PTX3 on angiogenesis
was also analysed by the in vivo CAM assay [15].
Indeed, PTX3 was able to inhibit angiogenesis induced
by the CM of primary MM PCs (which contains FGF2)
[25] by reducing vessel counts by 42% and 77% at 0.11
and 0.22 nM doses, respectively (Figure 4B). Overall,
the data indicate that PTX3 is able to inhibit FGF2-
dependent neovascularization in MM.
PTX3 down-regulates the FGF2 signalling and
cytokine secretion in MM ECs and FBs
Major signalling effector molecules in FGF2 pathways
such as phospho (p)-Akt, p-Erk1/2, p-Src, and p-NFκB
were examined in MM ECs and FBs upon PTX3
exposure. At 66 nm, PTX3 p-Src levels decreased by
22% in MM FBs, while p-Erk1/2 levels decreased by
20% in MM ECs (Figures 5A and 5B). At 132 nm,
PTX3 p-Akt and p-Src levels were respectively reduced
by 37% and 26% in MM ECs, and by 38% and 53% in
MM FBs (Figures 5A and 5B). A 47% reduction of p-
Erk1/2 was observed in MM ECs upon 132 nM PTX3
exposure. The p-NFκB levels were reduced by 50%
and 61% in MM ECs, and by 37% and 53% in MM
FBs at 66 and 132 nM PTX3, respectively (Figures 5A
and 5B). These data indicate that PTX3 significantly
prevents the activation of FGF2 downstream pathways
implicated in MM ECs and FB viability and migration.
PTX3 was next investigated for possible effects
on MM ECs’ and FBs’ secretion of the stromal cell
derived factor-1 alpha (SDF-1α), interleukin-8 (IL-
8), interleukin-6 (IL-6), and monocyte chemotactic
protein-1 (MCP-1), which are all involved in MM
progression [26,27]. As shown in Figure 5C, SDF-1α
secretion was reduced by 26% and 40% in CM of MM
ECs, and by 49% and 61% in CM of MM FBs at 66
and 132 nM PTX3, respectively. IL-8 was lowered by
22% and 33% in CM of MM ECs, and by 27% and
36% in CM of MM FBs at the same above doses.
Finally, MCP-1 was decreased by 20% and 27% in
PTX3-treated MM ECs.
PTX3 impacts MM PC viability and adhesion
Since the MM BM microenvironment is the source of
an intricate network of signals (via adhesion molecules
and cytokines) which support PC viability, prolifer-
ation, and migration, we wondered whether PTX3
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Figure 4. PTX3 inhibits angiogenesis in Matrigel
®
and chick embryo chorioallantoic membrane (CAM) assays. (A) MM endothelial cells
(ECs) from 18 patients were seeded on Matrigel
®
in serum-free medium (SFM) and SFM supplemented with FGF2 (0.58 nM) and PTX3
doses. After an 8 h incubation, inhibition of vessel mesh areas, length, and branching points was examined by image analysis software.
∗p < 0.03, ∗∗p < 0.01; Wilcoxon signed-rank test. Matrigel® pictures from a representative patient are shown. (B) CAMs were treated
with sponges loaded with SFM (negative control: physiological angiogenesis) or MM plasma cell (PC) conditioned media from 10 MM
patients in the absence or presence of 0.11 and 0.22 nM PTX3. Angiogenesis was measured and is expressed as mean ± SD vessel counts.
∗p < 0.03, ∗∗p < 0.01; Wilcoxon signed-rank test.
affected the viability of MM cells and their adhe-
sion to BMSCs. Flow cytometry analysis of PTX3-
treated PC lines demonstrated that direct treatment
with PTX3 reduced only marginally the viability of
MM PCs. Specifically, apoptosis in untreated control
RPMI8226 cells was 12% (Figure 6A, picture I) and
exposure to 66 and 132 nM PTX3 caused only a lim-
ited increase in the apoptotic index (27% and 29%,
respectively; Figure 6A, II and III). On this basis, to
assess whether PTX3 may affect MM PC viability indi-
rectly, ie via inhibition of ECs and FBs, RPMI8226
cells were co-cultured with these BMSCs, exposed to
PTX3, and assessed for apoptosis. In a first set of
experiments, RPMI8226 cells were co-cultured with
MM ECs and FBs separated by a transwell insert to
prevent cell–cell contact in the absence or in the pres-
ence of PTX3. Under these experimental conditions,
we observed no changes in the apoptotic index of
co-cultured RPMI8226 cells compared with the cell
line alone (Figure 6A, IV–VI). On the contrary, when
RPMI8226 cells were co-cultured without the transwell
insert to allow direct cell–cell contact with BMSCs,
66 and 132 nM PTX3 were able to induce apoptosis in
PCs by increasing the RPMI8226 cell apoptotic index
to 38% and 62%, respectively (Figure 6A, VII–IX). A
similar behaviour was observed in the U266 cell line
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Figure 5. PTX3 modulates FGF2-signalling pathway and cytokine secretion by MM endothelial cells (ECs) and fibroblasts (FBs). (A, B) MM
ECs (A) and FBs (B) purified from the BM of 15 patients were treated for 15 min with PTX3 (0, 66, and 132 nM) in serum-free medium
(SFM) supplemented with FGF2 (0.58 nM) and studied for expression of Akt, phospho (p)-Akt, Src, p-Src, Erk1/2, and p-Erk1/2 by western
blot. NFκB and p-NFκB were evaluated by treating MM ECs and FBs for 25 min with PTX3 (0, 66, and 132 nM) in serum-free medium (SFM)
supplemented with FGF2 (0.58 nM) and then treated with TNF-α (10 ng/ml) for 10 min. α-tubulin = loading control. Densitometry values
are shown as fold decrease compared with the control. Gels of cells from a representative patient are shown. (C) Measurement of the
indicated cytokines in the conditioned media of MM ECs and FBs was performed by ELISA. ∗p < 0.03, ∗∗p < 0.01; Wilcoxon signed-rank
test. SDF-1α, stromal cell derived factor-1 alpha; IL-6, interleukin-6; IL-8, interleukin-8; MCP-1, monocyte chemotactic protein-1.
(data not shown). The effect of PTX3 on MM ECs and
FBs co-cultured with RPMI8226 cells (with or without
transwell) was also analysed. As shown in Figure 6A,
X–XII, exposure to 66 and 132 nM PTX3 induced a
significant increase in the apoptotic index (36% and
57%, respectively) that was not modified either in the
presence or in the absence of a transwell insert (data
not shown). In order to confirm the PTX3 effect also on
primary MM cells, flow cytometry analysis of PTX3-
treated fresh PCs alone or co-cultured with paired MM
ECs and FBs was performed (Supplementary Figure 4).
The basal apoptosis percentage of PCs was higher than
that of cell lines due to their intrinsic frailty, and this
was prevented by co-culture with stromal cells (27%
versus 11% apoptotic cells, Supplementary Figure 4, I
and IV). 66 and 132 nM PTX3 were able to increase
Copyright © 2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 87–98
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
94 A Basile et al
MM endothelial cells MM fibroblasts
100
80
60
40
20
0
RPMI8226
MM ECs 0 66 132
PTX3 (nM)
CD11a expression on:
0 66 132 0 66 132 0 66 132 RPMI8226
MM FBs 0 66 132
PTX3 (nM)
0 66 132 0 66 132 0 66 132
RPMI8226 adhesion on:
%
 o
f a
dh
er
en
t
R
PM
I8
22
6 
ce
lls
100
80
60
40
20
0
%
 o
f a
dh
er
en
t
R
PM
I8
22
6 
ce
lls
Isotype control
+ PTX3 132 nM
+ PTX3 66 nM
- PTX3
+
 P
TX
3 
13
2 
nM
+
 P
TX
3 
66
 n
M
-
 
PT
X3
SF
M
 +
 F
G
F2
Isotype control
+ PTX3 132 nM
+ PTX3 66 nM
- PTX3S
FM
 +
 F
G
F2
RPMI8226 MFI =
0
7
9
19
MFI =
0
36
47
123
U266
Se
ru
m
-fr
ee
 m
ed
iu
m
 +
 F
G
F2
RPMI8226 in co-culture with MM ECs and FBs
RPMI8226
alone with transwell without transwell
MM ECs
and FBs
Apoptotic effect of PTX3 on RPMI8226 and MM endothelial cells and fibroblasts
Annexin V
7-
AA
D
100 101 102 103
102 103 104 105
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
102 103 104 105 102 103 104 105 102 103 104 105
102 103 104 105 102 103 104 105 102 103 104 105 102 103 104 105
102 103 104 105 102 103 104 105 102 103 104 105 102 103 104 105
100 101 102 103
I 12% IV 17% VII 11% X 15%
II 27% V 26% VIII 38% XI 36%
III 29% VI 27% IX 62% XII 57%
Q3 Q3
A
B
C
Figure 6. PTX3 affects plasma cell (PC), endothelial cell (EC), and fibroblast (FB) apoptosis and PC adhesion to MM ECs and FBs.
(A) Apoptosis of RPMI8226 and MM ECs and FBs. RPMI8226 cells alone (I–III), RPMI8226 co-cultured with ECs and FBs (IV–IX), and ECs
and FBs alone (X–XII) purified from 16 MM patients were seeded in serum-free medium (SFM) and SFM supplemented with 0.58 nM FGF2
and PTX3 (0, 66, and 132 nM). Co-cultures were performed with or without a transwell insert. After 24 h of PTX3 treatment, apoptosis of
RPMI8226 cells and of MM ECs and FBs (X–XII) was analysed by flow cytometry using Annexin-V/7-AAD. Green rectangles show early
(bottom box) and late (top box) apoptotic cells. Dot plots of BM ECs and FBs from a representative MM patient are shown. (B) Adhesion
assay of RPMI8226 cells on MM ECs and FBs. RPMI8226 cells and MM ECs and FBs were treated for 24 h with PTX3 (0, 66, and 132 nM)
in SFM added with 0.58 nM FGF2. RPMI8226 cells, labelled with Calcein AM Fluorescent Dye, were seeded onto 96-well plates coated
with MM ECs and FBs for 2 h to allow adhesion. Adherent PCs were analysed by a fluorescence assay. ∗p < 0.03, ∗∗p < 0.01; Wilcoxon
signed-rank test. (C) CD11a (LFA-1) expression on RPMI8226 and U266 cells cultured for 24 h in SFM supplemented with FGF2 (0.58 nM)
and PTX3 (0, 66, and 132 nM) was evaluated by flow cytometry. MFI = mean fluorescence intensity.
Copyright © 2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 87–98
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
PTX3 in multiple myeloma 95
apoptosis by 36% and 49%, respectively (Supplemen-
tary Figure 4, II and III). When PCs were co-cultured
with paired stromal cells, PTX3 produced a higher
apoptotic effect: 53% and 68%, respectively (Supple-
mentary Figure 4, V and VI).
We then examined whether PTX3 can affect MM
PC adhesion to ECs and FBs. As shown in Figure 6B,
adhesion of PTX3-treated RPMI8226 was markedly
inhibited in a dose-dependent fashion on both untreated
and treated MM ECs and FBs. On the contrary, no
effect was observed when untreated RPMI8226 cells
were seeded on treated MM ECs and FBs. The loss
of adhesive capability was mainly due to the down-
regulation of lymphocyte function-associated antigen-
1 (LFA-1/CD11a) expression on both PC lines. In
fact, flow cytometry analysis showed that treatment of
RPMI8226 and U266 cell lines inhibits the percentage
of CD11a+ cells as well as their mean fluorescence
intensity (Figure 6C). The expression of other adhe-
sive molecules, ie CD54, CD49d, CD49e, and CD29,
on PC lines (Supplementary Figure 5) and on MM ECs
and FBs (Supplementary Figure 6) did not vary signif-
icantly.
These data suggest that PTX3 drives both a direct
apoptotic effect on MM ECs and FBs and an indirect
apoptotic effect on PCs through its capability to inhibit
PC/BMSC adhesion.
Discussion
The superfamily of FGFs/FGFRs controls a wide range
of biological functions [27]. Specifically, FGF2 is a
pleiotropic growth factor that acts in an autocrine
and paracrine fashion on the tumour, stroma, and
inflammatory cells of several neoplastic diseases [26]
including MM [27]. High FGF2 levels are required
for vascular sprouting and integrity, while inhibition
of FGFR signalling causes angiostasis and vessel
disassembly [28]. FGF2 also favours VEGF to exert
its pro-angiogenic effect on ECs [29]. In MM, the
FGF2 levels are significantly higher in PC lysates of
patients with active disease compared with those with
non-active disease and MGUS, and inhibition of FGF2
suppresses the angiogenic potential of PCs, suggesting
a key role for these cells in the angiogenic switch
[25]. Overall, the data also indicate that FGF2 may
directly or indirectly stimulate MM PC survival and
proliferation and be considered a plausible therapeutic
target [26].
PTX3 is a natural selective antagonist for a restricted
number of FGF family members, inhibiting FGF2 but
not FGF1 or FGF4 activity [13]. PTX3 levels increase
under inflammatory conditions caused by infection,
tissue damage, and cancer [30–32]. Accordingly, here
we show that MM PCs, ECs, and FBs secrete increased
levels of PTX3 as well as FGF2. Analysis of data as
FGF2/PTX3 ratio demonstrated that in MM this ratio
is shifted towards the FGF2 production according to
the pro-angiogenic and inflammatory state of BM MM
compared with BM MGUS and control subjects.
To elucidate the effects of PTX3 on PC/stroma
cross-talk, we analysed BMSCs such as ECs and FBs
as well as PCs from MM and MGUS patients for
(i) responsiveness to exogenous PTX3 and (ii) changes
in the downstream signalling of the FGF2/FGFR sys-
tem upon exposure to PTX3. Overall, the study aimed
at identifying and testing a potential anti-angiogenic
and anti-PC role of PTX3 in MM that could suggest it
as a potential therapeutic target. MM ECs were used as
over-angiogenic ECs as opposed to MGUS ECs, con-
trol subjects’ ECs, and HUVECs, the norm-angiogenic
counterpart [4,19].
Our results demonstrate that PTX3 inhibits FGF2-
induced angiogenesis of MM ECs through its binding
to FGF2 (Figure 4). It does not affect VEGF-dependent
angiogenesis, since it is not able to interact with
VEGF (Figure 3), in line with Rusnati et al ’s data on
HUVECs and bovine aortic ECs [15]. We have also
shown that PTX3 impacts some biological functions
of ECs and FBs isolated from the BM of MM patients
(Figure 2) by inhibiting their viability and FGF2-
induced migration. Indeed, we demonstrated that PTX3
effects were mediated by down-regulation of several
FGF2-induced downstream signalling pathways, such
as p-Akt, p-Erk1/2, p-Src, and p-NFκB (Figure 5). The
effects of PTX3 on MGUS ECs and FBs were only
marginal, suggesting that these cells are not addicted
to FGF2/FGFR pathways.
Since the BM microenvironment plays a crucial
role in PC proliferation, survival, and drugs resistance,
we wondered whether PTX3 could indirectly hit PCs
through its inhibitory activity on BMSCs. We found
that PTX3 treatment is has as much negligible direct
cytotoxicity on MM cell lines as much as on fresh
PCs, but it induces significant PC apoptosis when these
cells are directly co-cultured with MM ECs and FBs
(Figure 6 and Supplementary Figure 4). It has been
already demonstrated that FGF2 promotes the stro-
mal cell derived factor-1 alpha (SDF-1α) production
through overexpression of its transcript via the ERM
transcription factor [33], and stimulates at least four to
five times the monocyte chemotactic protein-1 (MCP-
1) production in bovine aortic endothelial cells [34].
Tentatively, we hypothesize that the cytotoxic effect
of PTX3 may depend on its ability to (i) sequestrate
FGF2 with consequent reduction of SDF-1α, MCP-1,
and IL-8 production by both ECs and FBs (Figure 4);
(ii) down-regulate the expression of LFA-1 on MM
PCs (Figure 6); and (iii) induce the apoptosis of MM
ECs and FBs (Figure 6). It is thus plausible that
PTX3 exerts an indirect BMSC-mediated effect on
PCs, reducing their supply and chemotactic stimuli,
impairing the adhesive PC capability, and causing their
detachment from stromal ECs and FBs.
The BM microenvironment is the source of a com-
plex pattern of signals in which PCs and BMSCs recip-
rocally communicate, resulting in a feeder for PCs. In
this context, cytokines (such as FGF2, SDF-1α, IL-6,
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IL-8, and MCP-1) become fundamental since they act
in an autocrine and paracrine fashion on PCs. Human
MM cell lines (RPMI8226 and U266) did not show
constitutive FGFR activation nor did they activate pro-
liferation or survival after FGF2 stimulation, ruling out
possible autocrine or paracrine FGF2-mediated loops in
these cell lines.
In conclusion, we have shown a potent PTX3 anti-
angiogenic effect on MM ECs, due to its capability
to bind to FGF2 [15], and a direct impact on FGF2-
induced biological activities on MM FBs which also
support PC growth. PTX3 is cytotoxic on MM cells
by inhibiting the activities of ECs and FBs including
cytokine production, and causing loss of adhesive PC
capability to these cells. Thus, PTX3 may play an
important role in inhibiting the cross-talk between these
BMSCs and PCs in patients with MM.
Our data also suggest that at the angiogenic switch
MM ECs acquire high expression/activation of the
FGF2 signalling, which contributes to pathological BM
angiogenesis and overcomes the inhibitory effect of
the PTX3 autocrine loops usually activated to self-
limit physiological angiogenesis in a normal subject
or MGUS patient. Kumar et al [35] hypothesized an
inhibitory (anti-angiogenic) activity in MGUS patients
that is lost with the angiogenic switch, ie with transi-
tion to MM. We suggest that the expression of PTX3 by
MGUS ECs may be a self-limiting feature of MGUS
angiogenesis, which is overcome by high expression
of FGF2 at the angiogenic switch when MGUS ECs
are driven towards an MM EC over-angiogenic pheno-
type by PCs and BMSCs. The exposure of MM ECs to
exogenous PTX3 appears to re-equilibrate the abnor-
mal excess of endogenous FGF2 and leads them to a
norm-angiogenic state like MGUS ECs, control ECs,
and HUVECs.
Indeed, FGF2-induced proliferation, migration, and
angiogenesis on the Matrigel® surface and in the CAM
were also significantly inhibited by recombinant PTX3.
Hence, recombinant PTX3, acting as an agent aimed at
blocking excessive FGF2 activity and re-establishing
a physiological FGF2/PTX3 ratio, may be a possible
future area of research in the field of anti-angiogenesis
in MM.
This study shows limitations that we wish to cover.
We will evaluate the PTX3 effects in MM patients in
relation to the D&S stage. Also, we have planned to
apply PTX3 to an in vivo model other than CAM, ie
the NOD-scid MM mouse, in order to study better its
anti-MM and anti-angiogenic effects. Finally, we will
evaluate the activity of PTX3 in conjunction with the
new anti-MM drugs, such as bortezomib, thalidomide,
and lenalidomide, to assess its potential additive or
synergistic effects in inhibiting plasma cell/stromal cell
cross-talk.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article.
Supplementary materials and methods
Figure S1. PTX3 effects on MGUS and normal endothelial cell (EC) functional activities.
Figure S2. PTX3 effects on MGUS and normal fibroblast (FB) functional activities.
Figure S3. PTX3 effects on MGUS and normal endothelial cell (EC) angiogenesis.
Figure S4. PTX3 affects apoptosis of fresh MM plasma cells (PCs).
Figure S5. Expression of the indicated adhesion molecules on RPMI8226 and U266 cells upon PTX3 treatment.
Figure S6. Expression of the indicated adhesion molecules on MM ECs and FBs upon PTX3 treatment.
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